OBJECTIVE: Infrequent Pap screening is an important risk factor for cervical cancer. We studied the association between contraceptive methods, screening frequency, and cancer. METHODS: Women (n=2004) enrolled in the cross-sectional Study to Understand Cervical Cancer Endpoints and Determinants (SUCCEED) underwent colposcopy to evaluate an abnormal Pap test. Questionnaire data were compared between those with cervical intraepithelial neoplasia (CIN) 3/adenocarcinoma in situ (AIS) and those with invasive cancer to identify factors associated with cancer. Logistic regression was used to calculate age-stratified measures of association between contraceptive method and Pap frequency as well as tubal ligation (TL) and cancer risk. RESULTS: In all age groups, women with TL were more likely to have had no Pap screening in the previous 5 years compared to women using other contraception: 26-35 years (OR 4.6, 95% CI 2.4-8.6; p<0.001), 36-45 years (OR 3.8, 95% CI 2.1-7.0; p<0.001), and 46-55 years (OR 2.2, 95% CI 1.0-4.9; p=0.050). Subjects with cancer (n=163) were more likely to have had a TL (41% vs. 21%, p<0.001) than those with CIN 3/AIS (n=370). Age-stratified analyses showed increased odds of tubal ligation in women with cancer versus those with CIN 3/AIS between 25 and 45 years, with a significant increase in women 26 to 35 years old (OR 3.3, 95% CI 1.4-8.1; p=0.009). Adjusting for Pap frequency changed the effect only slightly, suggesting that increased risk was not fully mediated by lack of screening. CONCLUSION: Contraceptive type is associated with Pap screening. Women with TLs obtain less frequent Pap testing and may be at an increased risk for cervical cancer.
OBJECTIVE: Infrequent Pap screening is an important risk factor for cervical cancer. We studied the association between contraceptive methods, screening frequency, and cancer. METHODS:Women (n=2004) enrolled in the cross-sectional Study to Understand Cervical Cancer Endpoints and Determinants (SUCCEED) underwent colposcopy to evaluate an abnormal Pap test. Questionnaire data were compared between those with cervical intraepithelial neoplasia (CIN) 3/adenocarcinoma in situ (AIS) and those with invasive cancer to identify factors associated with cancer. Logistic regression was used to calculate age-stratified measures of association between contraceptive method and Pap frequency as well as tubal ligation (TL) and cancer risk. RESULTS: In all age groups, women with TL were more likely to have had no Pap screening in the previous 5 years compared to women using other contraception: 26-35 years (OR 4.6, 95% CI 2.4-8.6; p<0.001), 36-45 years (OR 3.8, 95% CI 2.1-7.0; p<0.001), and 46-55 years (OR 2.2, 95% CI 1.0-4.9; p=0.050). Subjects with cancer (n=163) were more likely to have had a TL (41% vs. 21%, p<0.001) than those with CIN 3/AIS (n=370). Age-stratified analyses showed increased odds of tubal ligation in women with cancer versus those with CIN 3/AIS between 25 and 45 years, with a significant increase in women 26 to 35 years old (OR 3.3, 95% CI 1.4-8.1; p=0.009). Adjusting for Pap frequency changed the effect only slightly, suggesting that increased risk was not fully mediated by lack of screening. CONCLUSION: Contraceptive type is associated with Pap screening. Women with TLs obtain less frequent Pap testing and may be at an increased risk for cervical cancer.
Authors: Thomas C Wright; J Thomas Cox; L Stewart Massad; Jay Carlson; Leo B Twiggs; Edward J Wilkinson Journal: J Low Genit Tract Dis Date: 2003-07 Impact factor: 1.925
Authors: Meg Watson; Mona Saraiya; Vicki Benard; Steven S Coughlin; Lisa Flowers; Vilma Cokkinides; Molly Schwenn; Youjie Huang; Anna Giuliano Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Margaret R E McCredie; Katrina J Sharples; Charlotte Paul; Judith Baranyai; Gabriele Medley; Ronald W Jones; David C G Skegg Journal: Lancet Oncol Date: 2008-04-11 Impact factor: 41.316
Authors: Nicolas Wentzensen; Mark Schiffman; S Terence Dunn; Rosemary E Zuna; Joan Walker; Richard A Allen; Roy Zhang; Mark E Sherman; Sholom Wacholder; Jose Jeronimo; Michael A Gold; Sophia S Wang Journal: Int J Cancer Date: 2009-02-15 Impact factor: 7.396
Authors: Sophia S Wang; Rosemary E Zuna; Nicolas Wentzensen; S Terence Dunn; Mark E Sherman; Michael A Gold; Mark Schiffman; Sholom Wacholder; Richard A Allen; Ingrid Block; Kim Downing; Jose Jeronimo; J Daniel Carreon; Mahboobeh Safaeian; David Brown; Joan L Walker Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01 Impact factor: 4.254
Authors: Shu-Yuan Liao; William H Rodgers; James Kauderer; Thomas A Bonfiglio; Joan L Walker; Kathleen M Darcy; Randy Carter; Masayuji Hatae; Lyuba Levine; Nick M Spirtos; Eric J Stanbridge Journal: Int J Cancer Date: 2009-11-15 Impact factor: 7.396
Authors: Patricia Luhn; Joan Walker; Mark Schiffman; Rosemary E Zuna; S Terence Dunn; Michael A Gold; Katherine Smith; Cara Mathews; Richard A Allen; Roy Zhang; Sophia Wang; Nicolas Wentzensen Journal: Gynecol Oncol Date: 2012-11-10 Impact factor: 5.482
Authors: Vicki B Benard; J Elizabeth Jackson; April Greek; Virginia Senkomago; Warner K Huh; Cheryll C Thomas; Lisa C Richardson Journal: Cancer Med Date: 2021-05-21 Impact factor: 4.452
Authors: Kezia Gaitskell; Kate Coffey; Jane Green; Kirstin Pirie; Gillian K Reeves; Ahmed A Ahmed; Isobel Barnes; Valerie Beral Journal: Br J Cancer Date: 2016-04-21 Impact factor: 7.640